Eli Lilly CEO Opposes Congressional Codification of Trump's Most Favored Nation Drug Pricing Deals
核心洞察
Eli Lilly CEO Dave Ricks (搜索) opposes White House (搜索) efforts to codify "most favored nation" drug pricing agreements into permanent legislation, despite the company signing such a deal with the Trump administration (搜索).
Ricks expressed concerns that congressional involvement would alter the original agreements and potentially harm America's pharmaceutical research capabilities and drug industry robustness.
The CEO warned that lawmakers prioritize immediate price reductions over long-term innovation, stating Lilly will use "all the tools we have to combat bad policy."
Eli Lilly CEO Dave Ricks (搜索) has publicly opposed the White House (搜索)'s efforts to transform voluntary "most favored nation" drug pricing agreements into permanent federal law, marking a significant shift in the pharmaceutical industry's stance on Trump-era pricing policies.
Industry Resistance to Legislative Codification
In an interview with CNBC (搜索), Ricks expressed strong reservations about congressional involvement in drug pricing agreements that were originally negotiated as voluntary deals between pharmaceutical companies and the Trump administration (搜索). "When you throw it into the congressional process, what goes in is not what's going to come out," Ricks said.
Lilly is among more than a dozen drugmakers that signed agreements with the Trump administration (搜索) last year, committing to charge similar prices for prescription drugs in the U.S. as in other wealthy nations. These deals were designed to address President Donald Trump's long-standing complaint that Americans pay high prices to subsidize low prices for medicine in the rest of the world.
Concerns Over Innovation and Industry Impact
Ricks articulated specific concerns about the potential consequences of legislative action, warning that congressional involvement could undermine America's pharmaceutical research capabilities. "I think we see a lot of people who would rather reduce prices today and not worry about whether we have any new medicines tomorrow, not worry about whether America will have a robust drug industry and we'll be able to do research in this country," he stated.
The CEO emphasized that these considerations drive Lilly's opposition to the legislative push, saying, "And I worry about those things, so I don't think that's a great idea, and we've been pretty clear with the administration and the congressional leaders about that."
Strategic Industry Miscalculation
The pharmaceutical industry's original strategy appears to have backfired. Companies initially believed that signing voluntary agreements would satisfy political pressure and prevent attempts to make "most favored nation" pricing mandatory through legislation. However, the White House (搜索) has recently pushed Congress to codify elements of these deals into law.
While the administration has not publicly shared the draft legislative text, officials have indicated they are seeking pharmaceutical company support for the effort. The administration has stated it is working to get industry backing, but Lilly's position demonstrates significant resistance within the sector.
Company's Advocacy Strategy
Ricks indicated that while he believes the Trump administration (搜索) and congressional leadership are listening to the company's concerns, Lilly is prepared to take a more aggressive stance if necessary. "We'll use all the tools we have to combat bad policy, and we think it would be bad policy," he said.
The CEO's comments represent one of the most direct public challenges to the White House (搜索)'s drug pricing legislative agenda from a major pharmaceutical company that previously participated in the voluntary agreement program.